Bevacizumab Inhibits Angiogenesis and Inflammation in Rat Filtration Surgery Model.
Bevacizumab can be potentially applied in filtration surgery in glaucoma patients. However, its mechanism remains unclear. In order to explore it, here, we established rat filtration surgery model and treat rat with Bevacizumab. At different time points after surgery, filtering blebs were collected and subjected to angiogenesis and inflammation genes analysis. Our results found that Bevacizumab significantly improved the outcome of filtration surgery and reduced complications (P < 0.05). Furthermore, angiogenesis factor, VEGF, and inflammation factors, TGFβ1 and TGFβ2, were dramatically inhibited by Bevacizumab treatment according to analysis of real-time PCR and western blot. Altogether, our findings suggested that Bevacizumab's beneficial effects on filtration surgery were not limited to antiangiogenesis effect and anti-inflammation effects may be also involved.